<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303522</url>
  </required_header>
  <id_info>
    <org_study_id>20120299</org_study_id>
    <nct_id>NCT02303522</nct_id>
  </id_info>
  <brief_title>Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)</brief_title>
  <official_title>A Retrospective Pooled Analysis of Complete Remission Among Pediatric Patients With Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An historical data comparator study for children with relapsed/refactory acute lymphoblastic
      leukemia (ALL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A retrospective observational study reviewing historical complete remission for pediatric
      patients who had either relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hematological Complete Remission (CR)</measure>
    <time_frame>Approx. 1 year</time_frame>
    <description>To estimate hematological Complete Remission (CR) in pediatric patients with relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia (ALL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Approx. 1 year</time_frame>
    <description>OS following salvage therapy: defined as time to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular CR</measure>
    <time_frame>Approx. 1 year</time_frame>
    <description>Defined as MRD &lt;10-4 measured either by PCR or flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Free Survival (RFS)</measure>
    <time_frame>Approx. 1 year</time_frame>
    <description>Defined as time to relapse or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hematological CR</measure>
    <time_frame>Approx. 1 year</time_frame>
    <description>Defined as time to unequivocal detection of &gt;5% leukemia cells in bone marrow as measured by cytological, microscopic assessment, presence of circulating leukemia blasts, or extramedullary leukemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receipt of HSCT after salvage treatment</measure>
    <time_frame>Approx. 1 year</time_frame>
    <description>Defined as the receipt of HSCT after chemotherapy or a previously failed HSCT.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">207</enrollment>
  <condition>B-cell Precursor Acute Lymphoblastic Leukemia (ALL)</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <description>All subjects will be included in a unique cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Other: not applicable - observational study</intervention_name>
    <description>No intervention exists as this is a retrospective observational study</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Pediatric (age less than 18 years) patients with relapsed or refractory B-cell
             precursor ALL, specifically those with

          -  2nd or later relapse after chemotherapy (with no prior transplantation),

          -  Relapse after HSCT, or

          -  Refractory disease

          -  Had treatment for relapsed or refractory disease between 2005-2012

          -  Has data available on ALL treatment, including number of salvage treatments, response
             status after therapies, and HSCT

        Exclusion criteria:

          -  No CNS involvement at relapse

          -  No previous treatment with blinatumomab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>November 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2014</study_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALL, pediatric, leukemia, childhood, lymphoblastic, lymphoma, acute, Precursor Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

